16.82USD+1.20%Mkt Cap: 13.25B USDP/E: —Last update: 2026-05-26
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap13.25B USD
Enterprise Value12.98B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.08B USD
Revenue/Share—
Last Price16.82 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees265
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.11
PEG—
EV/EBITDA-10.62
EV/Revenue—
P/S—
P/B24.82
EPS (TTM)-1.60
EPS (Forward)-1.15
52W Range
13.8317% of range30.98
52W High30.98 USD
52W Low13.83 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-163.86%
ROA-143.72%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-322.93M USD
CapEx (TTM)657.00K USD
FCF Margin—
FCF Yield0.53%
Net Debt-578.69M USD
Net Debt/EBITDA0.47
Balance Sheet
Debt/Equity0.03
Current Ratio7.41
Quick Ratio7.19
Book Value/Sh0.7040 USD
Cash/Share0.7710 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Target (Mean)29.62 USD
Target Range11.92 USD – 45.08 USD
# Analysts13
Ownership
Shares Out.776.16M
Float134.66M
Insiders82.64%
Institutions15.86%
Short Interest
Short Ratio7.6d
Short % Float21.65%
Short % Out.3.76%
Shares Short29.19M
Short (prev mo.)34.56M
Technical
SMA 5018.87 (-10.8%)
SMA 20019.03 (-11.6%)
Beta-1.25
S&P 52W Chg28.31%
Avg Vol (30d)4.76M
Avg Vol (10d)3.22M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—